GV-971 prevents severe acute pancreatitis by remodeling the microbiota-metabolic-immune axis

Xi Chen, Xin Chen, Ding Yan, Na Zhang, Wen Fu, Meixuan Wu, Feifei Ge, Jiangtuan Wang, Xiaofen Li, Meiyu Geng, Jinheng Wang (), Daolin Tang () and Jinbao Liu ()
Additional contact information
Xi Chen: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Xin Chen: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Ding Yan: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Na Zhang: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Wen Fu: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Meixuan Wu: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Feifei Ge: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Jiangtuan Wang: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Xiaofen Li: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Meiyu Geng: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Jinheng Wang: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University
Daolin Tang: UT Southwestern Medical Center
Jinbao Liu: State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University

Nature Communications, 2024, vol. 15, issue 1, 1-18

Abstract: Abstract Despite recent advances, severe acute pancreatitis (SAP) remains a lethal inflammation with limited treatment options. Here, we provide compelling evidence of GV-971 (sodium oligomannate), an anti-Alzheimer’s medication, as being a protective agent in various male mouse SAP models. Microbiome sequencing, along with intestinal microbiota transplantation and mass cytometry technology, unveil that GV-971 reshapes the gut microbiota, increasing Faecalibacterium populations and modulating both peripheral and intestinal immune systems. A metabolomics analysis of cecal contents from GV-971–treated SAP mice further identifies short-chain fatty acids, including propionate and butyrate, as key metabolites in inhibiting macrophage M1 polarization and subsequent lethal inflammation by blocking the MAPK pathway. These findings suggest GV-971 as a promising therapeutic for SAP by targeting the microbiota metabolic immune axis.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52398-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52398-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52398-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().